Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia
Medical and Pediatric Oncology, Volume 3, No. 4, Year 1977
Notification
URL copied to clipboard!
Description
Between 1971 and 1974, 646 evaluable patients under 20 years of age with previously untreated acute lymphocytic leukemia were treated according to Cancer and Leukemia Group B (formerly Acute Leukemia Group B) Protocol 7111. On a random basis, they received a 10‐day course of 1,000 units/kg/day of L‐asparaginase before, during, or after a 3‐week course of vincristine and corticosteroid. A control group received vincristine and corticosteroid for 4 weeks but no asparaginase. The overall complete remission rate was 85%, which was not altered significantly by any of the induction variables. Patients who received asparaginase for 10 days subsequent to vincristine and corticosteroid had a significantly longer complete remission duration with an estimated median of 45 months, compared to 20 months for the group receiving no asparaginase and 27 months for the other 2 asparaginase regimens. The beneficial effect of asparaginase was noted, irrespective of which 1 of the 2 intensification and maintenance programs the patients received. The 5‐year projection indicates a complete remission rate of 50% for those patients receiving subsequent asparaginase as compared to 41% of those induced on other regimens in this study and thus is superior to the use of only vincristine and corticosteroid. Copyright © 1977 Wiley‐Liss, Inc., A Wiley Company
Authors & Co-Authors
Jones, Barbara T.
United States, Morgantown
West Virginia University School of Medicine Morgantown
Holland, James F.W.
Unknown Affiliation
Glidewell, Oliver J.
Unknown Affiliation
Jacquillat, Claude I.
Unknown Affiliation
Weil, Marise
Unknown Affiliation
Pochedly, Carl E.
Unknown Affiliation
Sinks, Lucius F.
Unknown Affiliation
Chevalier, Louise M.
Unknown Affiliation
Maurer, Harold M.
Unknown Affiliation
Koch, Kjell
Unknown Affiliation
Falkson, Geoffrey G.
Unknown Affiliation
Patterson, Richard B.
Unknown Affiliation
Seligman, Barbara R.
Unknown Affiliation
Sartorius, Jurg A.
Unknown Affiliation
Kung, Faith H.
Unknown Affiliation
Haurani, Farid I.
Unknown Affiliation
Stuart, Marie J.
Unknown Affiliation
Burgert, E. Omer
Unknown Affiliation
Ruymann, Frederick B.
Unknown Affiliation
Sawitsky, Authrur
Unknown Affiliation
Forman, Edwin N.
Unknown Affiliation
Pluess, Hansjuerg J.
Unknown Affiliation
Truman, John T.
Unknown Affiliation
Hakami, Nasrollah
Unknown Affiliation
Statistics
Citations: 75
Authors: 24
Affiliations: 1
Identifiers
Doi:
10.1002/mpo.2950030410
ISSN:
00981532
Research Areas
Cancer
Study Design
Randomised Control Trial